Pre-clinical profile of Porcupine inhibitor RXC004 presented at EORTC-NCI-AACR 2016
30 Nov 2016
Redx Pharma is pleased to announce that it will present the pre-clinical profile of its Porcupine inhibitor RXC004 at the 28th European Organisation for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) and American Association for Cancer Research (AACR) Symposium in Munich, Germany, on 30 November 2016.
Redx’s Porcupine inhibitor RXC004 exhibits potent and selective inhibition of the Wnt pathway in in vitro and in vivo models of Wnt dependant pancreatic cancer. Preliminary results indicate that RXC004 may also enhance the efficacy of checkpoint inhibitors, such as anti-PD-1 antibodies, by reducing the proportion of regulatory T cells in the tumour microenvironment and enhancing the ratio of cytotoxic T cells to regulatory T cells in tumour infiltrates.
Pre-clinical studies are ongoing to determine the effect of RXC004 on the immune response to cancer. The Company is progressing studies to prepare the RXC004 program for first-in-human clinical trials. The aim is to commence these, initially monotherapy, trials early 2017.
Dr Neil Murray, CEO of Redx, said:
We’re delighted to present the compelling pre-clinical profile of our Porcupine inhibitor RXC004 at the EORTC-NCI-AACR Symposium.
RXC004 has the potential to become a potent therapy for a subset of biliary, gastric and pancreatic cancer patients. It has also been shown to enhance the efficacy of checkpoint inhibitors, such as anti-PD-1 antibodies. We aim to initiate first-in-human clinical studies for RXC004 early 2017.
Details of the presentation:
- Date: 30 November 2016
- Time: 10:15-17:00
- Poster Session: Immunotherapy
- Poster Board Number: P131
- Poster Title: Novel Porcupine inhibitor RXC004: Potent efficacy in animal models of cancer through direct tumour targeting and immunomodulatory mechanisms